Compare DexCom, Inc. (DXCM) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs United Microelectronics Corp — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while United Microelectronics Corp trades at $22.24 (market cap $65.12B). The key difference: United Microelectronics Corp is far larger — about 2.3× DexCom, Inc.'s market cap, and United Microelectronics Corp pays a 1.65% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | UMC | |
|---|---|---|
Market Cap | $28.06B | $65.12B |
Sector | Health | Technology |
52-Week High | $89.53 | $28.02 |
52-Week Low | $54.84 | $6.58 |
Enterprise Value | $27.03B | $62.70B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
UMC trades at $22.26, down 6.63% over the past day, with a bullish technical signal driven by moving averages and positive momentum indicators. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains strong profitability with a 20.25% net income margin. Recent news highlights mass production milestones in silicon photonics and 14nm eHV FinFET platform advancements, supporting growth in AI and automotive demand.
Outlook remains positive with solid revenue growth and margin stability, though valuation ratios like P/E of 40.46 suggest premium pricing. Risks include competitive pressures and cyclical semiconductor demand. Analyst consensus is mixed with 26.7% buy ratings, indicating cautious optimism amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
